WHO suspends clinical trial with hydroxychloroquine

CNC
Added On May 29, 2020

 The World Health Organization Director-General Dr. Tedros has said that a clinical trial of a malaria drug on COVID-19 patients came to "a temporary pause" while the safety data is reviewed by the Data Safety Monitoring Board.

 
According to the WHO chief, the medical journal The Lancet has published an observational study on hydroxychloroquine and chloroquine and its effects on COVID-19 patients.
The authors of the study reported that among patients receiving the drug, when used alone or with a macrolide, they estimated a higher mortality rate.
 
The World Health Organization initiated the Solidarity Trial, a plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19 more than two months ago, which include hydroxychloroquine.